Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial to evaluate efficacy and safety of cyclophosphamide, bortezomib and dexamethasone (CBD) induction and autologous stem cell transplantation for patients for newly diagnosed multiple myeloma (NBMT-ASCT1201)

Next Previous
X
Search
Trial Profile

Clinical trial to evaluate efficacy and safety of cyclophosphamide, bortezomib and dexamethasone (CBD) induction and autologous stem cell transplantation for patients for newly diagnosed multiple myeloma (NBMT-ASCT1201)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Autologous stem cell therapy; Cyclophosphamide; Dexamethasone; Dexamethasone; Granulocyte colony-stimulating factors; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
    • 23 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top